Health‐related quality of life after open transhiatal and transthoracic oesophagectomy for cancer. BJS 2018; 105: 230-236.
Published: 5th February 2018
Authors: J. H. Kauppila, A. Johar, J. A. Gossage, A. R. Davies, J. Zylstra, J. Lagergren et al.
Transhiatal and transthoracic oesophagectomy in patients with oesophageal cancer have similar survival rates. Whether these approaches differ in health‐related quality of life (HRQoL) is uncertain and was examined in this study.
Patients undergoing transhiatal or transthoracic surgery for lower‐third oesophageal or gastro‐oesophageal junctional cancer between 2011 and 2015 were selected from an institutional database. HRQoL outcomes were measured at 6 and 12 months after surgery using validated written questionnaires (European Organisation for Research and Treatment of Cancer QLQ‐C30 and QLQ‐OG25). Linear mixed models provided mean score differences (MSDs) with 95 per cent confidence intervals, adjusted for preoperative HRQoL, age, physical status (ASA fitness grade), tumour location, tumour stage, neoadjuvant therapy, adjuvant therapy and postoperative complications. MSD values of 10 or more were regarded as clinically relevant.
Some 146 patients underwent transhiatal (86, 58·9 per cent) or transthoracic (60, 41·1 per cent) oesophagectomy. The HRQoL questionnaires were returned by 111 patients at 6 months and 74 at 12 months. At 6 months, transthoracic oesophagectomy was associated with worse role function (MSD –12, 95 per cent c.i. –23 to 0;
Transhiatal oesophagectomy seems to offer better HRQoL than transthoracic oesophagectomy 6 and 12 months after surgery.Full text
You may also be interested in
Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
Authors: B.‐Y. Wang, S.‐C. Wu, H.‐C. Chen, W.‐H. Hung, C.‐H. Lin, C.‐L. Huang et al.
Notes: Surgery after chemoradiation indicated
Effect of preoperative biliary drainage on cholestasis‐associated inflammatory and fibrotic gene signatures in perihilar cholangiocarcinoma.
Authors: M. J. Reiniers, L. de Haan, R. Weijer, J. K. Wiggers, A. Jongejan, P. D. Moerland et al.
Authors: L. Goense, J. Meziani, J. P. Ruurda, R. van Hillegersberg
Meta‐analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes.
Authors: M. Roman, A. Monaghan, G. F. Serraino, D. Miller, S. Pathak, F. Lai et al.
Notes: Possible but how much is enough?
Multicentre cohort study of antihypertensive and lipid‐lowering therapy cessation after bariatric surgery.
Authors: J. Thereaux, T. Lesuffleur, S. Czernichow, A. Basdevant, S. Msika, D. Nocca et al.
Notes: Better than controls
Authors: M. van Putten, S. D. Nelen, V. E. P. P. Lemmens, J. H. M. B. Stoot, H. H. Hartgrink, S. S. Gisbertz et al.
Notes: Practise makes perfect?
Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus.
Authors: S. Mine, M. Watanabe, K. Kumagai, A. Okamura, K. Yamashita, M. Hayami et al.
Notes: Extended dissection not needed
Authors: J. Zheng, S.‐H. Xie, G. Santoni, J. Lagergren
Notes: Diabetes increases risk
Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. BJS 2018; 105: 1639-1649.
Authors: A. R. Davies, D. Myoteri, J. Zylstra, C. R. Baker, W. Wulaningsih, M. Van Hemelrijck et al.
Notes: Nodal response predicts survival
Network meta‐analysis of surgical management of gastro‐oesophageal reflux disease in adults. BJS 2018; 105: 1398-1407.
Authors: M. A. Amer, M. D. Smith, C. H. Khoo, G. P. Herbison, J. L. McCall
Authors: H. Mackenzie, S. R. Markar, A. Askari, O. Faiz, M. Hull, S. Purkayastha et al.
Meta‐analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. BJS 2018; 105: 1408-1416.
Authors: N. T. E. Bird, A. McKenna, J. Dodd, G. Poston, R. Jones, H. Malik et al.
Notes: Tumour biology is important